Discover
CMPX
Compass Therapeutics, Inc.
2.31
71 x 2.31
144 x 2.32
bid
ask
+
0.09
4.16%
01:31 PM
timesize
| Ytd | -56.94% | |
| 1y | -30.77% |
2.21
day range
2.38
1.61
52 week range
6.88
| Open | 2.25 | Prev Close | 2.22 | Low | 2.21 | High | 2.38 | Mkt Cap | 416.90M |
| Vol | 2.34M | Avg Vol | 3.63M | EPS | -0.40 | P/E | -5.79 | Forward P/E | -10.86 |
| Beta | 0.92 | Short Ratio | 12.39 | Inst. Own | 88.00% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-05 | 50-d Avg | 2.10 | 200-d Avg | 4.15 | 1yr Est | 13.64 |
| Income Statement | |||
| Operating Expenses | 26.98M | ||
| Research and Development Expense | 19.58M | ||
| Selling, General and Administrative Expense | 7.40M | ||
| Operating Income | -26.98M | ||
| Net Income | -25.15M | ||
| Net Income Common Stock | -25.15M | ||
| Net Income Common Stock (USD) | -25.15M | ||
| Consolidated Income | -25.15M | ||
| Earnings per Basic Share | -0.13 | ||
| Earnings per Basic Share (USD) | -0.13 | ||
| Earnings per Diluted Share | -0.13 | ||
| Earning Before Interest & Taxes (EBIT) | -25.15M | ||
| Earning Before Interest & Taxes (USD) | -25.15M | ||
| Weighted Average Shares | 186.80M | ||
| Weighted Average Shares Diluted | 186.80M | ||
| Balance Sheet | |||
| Cash and Equivalents | 36.02M | ||
| Cash and Equivalents (USD) | 36.02M | ||
| Investments | 144.43M | ||
| Investments Current | 144.43M | ||
| Current Assets | 180.89M | ||
| Property, Plant & Equipment Net | 8.72M | ||
| Total Assets | 190.17M | ||
| Debt Current | 1.64M | ||
| Total Debt | 9.63M | ||
| Current Liabilities | 16.13M | ||
| Debt Non-Current | 8.00M | ||
| Total Liabilities | 24.12M | ||
| Accumulated Retained Earnings (Deficit) | -474.64M | ||
| Accumulated Other Comprehensive Income | -251.00K | ||
| Shareholders Equity | 166.05M | ||
| Shareholders Equity (USD) | 166.05M | ||
| Assets Non-Current | 9.28M | ||
| Total Debt (USD) | 9.63M | ||
| Liabilities Non-Current | 8.00M | ||
| Trade and Non-Trade Payables | 2.91M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 376.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -19.71M | ||
| Capital Expenditure | -176.00K | ||
| Net Cash Flow from Investing | -4.98M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -4.80M | ||
| Net Cash Flow from Operations | -14.74M | ||
| Share Based Compensation | 4.82M | ||